GlassScriptPhysician profile
Barry J Klyde
NPI 1831131358
$4,740.34
in general payments reported to CMS, 2019-2025
29 companies · $667 in 2025
The $667 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $291 · 2021: $792 · 2022: $624 · 2023: $1,053 · 2024: $842 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,540 · Education: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.20 |
| Education | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,819.89 | 2019-2025 | |
| Lilly USA, LLC | $818.63 | 2019-2025 | Mounjaro, Jardiance, Lyumjev |
| Novo Nordisk INC | $289.90 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $277.59 | 2019-2024 | Farxiga |
| Acella Pharmaceuticals, LLC | $275.16 | 2023-2025 | NP Thyroid 60 |
| Pfizer INC. | $255.37 | 2023-2025 | |
| Amgen INC. | $197.28 | 2019-2024 | Tepezza |
| Ibsa Pharma INC. | $140.02 | 2020-2024 | Tirosint, Licart, Tirosint |
| Antares Pharma, INC. | $94.94 | 2019-2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $82.38 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $73.54 | 2021-2024 | Strensiq |
| Kowa Pharmaceuticals America, INC. | $45.29 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $42.77 | 2024 | |
| Xeris Pharmaceuticals, INC. | $42.51 | 2022-2023 | Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $31.94 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $31.54 | 2021 | |
| Corcept Therapeutics | $24.33 | 2023 | Korlym |
| Ascendis Pharma Endocrinology INC | $21.78 | 2025 | Yorvipath |
| Abbott Laboratories | $20.50 | 2021 | |
| Verity Pharmaceuticals INC. | $18.70 | 2024 | Tlando |
| Azurity Pharmaceuticals, INC. | $17.13 | 2023 | Adthyza |
| Vistapharm, INC. | $17.11 | 2021 | |
| Horizon Therapeutics Plc | $16.60 | 2023 | Tepezza |
| Esperion Therapeutics, INC. | $15.93 | 2022 | |
| Amarin Pharma, INC. | $15.90 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.81 | 2021 | |
| Avion Pharmaceuticals | $15.01 | 2024 | NP Thyroid 60 |
| Biohaven Pharmaceutical Holding Company LTD. | $13.28 | 2022 | |
| Clarus Therapeutics INC. | $9.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Klyde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.